Akari Therapeutics

Akari Therapeutics and Whitehawk have launched a research collaboration to preclinically evaluate a combination of Akari’s PH1 spliceosome payload with Whitehawk’s topoisomerase‑I‑inhibitor ADC platform. Akari will be responsible for the design, conduct and analysis of the studies, which will assess compatibility and synergies of the dual payloads and serve as the basis for further development decisions. Akari is developing AKTX-101, a Trop2‑targeting PH1‑ADC, and has initiated IND studies with the aim of a first‑in‑human trial by mid‑2027. » More on de.investing.com

Akari Therapeutics received about 8.3 million USD in Q2 through a PIPE transaction led by existing investors (5.5 million USD) and option exercises (around 2.8 million USD). The company agreed to the sale or prefinancing of ADS and warrants; issuing further series of options requires shareholder approval at the upcoming annual general meeting. Akari reports a low liquidity ratio (current ratio 0.27) and a market capitalization of about 12.28 million USD, is developing AKTX-101 and AKTX-102 (ADC candidates), and aims to begin a first clinical study for AKTX-101 by mid-2027. » More on de.investing.com

Akari Therapeutics has announced a private placement expected to raise approximately $5.5 million; offered are 1,470,588 unregistered ADS or pre-funded warrants, as well as Series H, I and J warrants, at a price of $3.74 per ADS. Net proceeds are intended for working capital and to advance the antibody–drug conjugate AKTX-101 to a Phase 1 clinical trial. The financing will take place in three tranches (expected May 27 to July 15, 2026) and the issuance of the warrants requires shareholder approval; the company cites liquidity pressures with a market capitalization of $4.23 million and a current ratio of 0.27. » More on de.investing.com